The Natoli Institute for Industrial Pharmacy Research and Development Now Open
Natoli Engineering Company announces the opening of the Natoli Institute for Industrial Pharmacy Research and Development. Opened in partnership with the Arnold and Marie Schwartz College of Pharmacy and Health Sciences on the Brooklyn campus of Long Island University (LIU), the Natoli Institute features dispensing, formulation, compression, and coating suites.
Supporting one of the few industrial pharmacy programs in North America, the Institute is dedicated to advancing knowledge in the field of pharmaceutical solid oral dosage formulation and engineering.
“The facility features traditional solid dosage formulation equipment, as well as the technology to measure the physical and chemical properties of tablets,” said Dr. Chuck Kettler PhD, director of Natoli Scientific.
Natoli established the Institute to further pharmaceutical compression science and support research into the industry’s most complex challenges. The laboratory will provide research opportunities to undergraduate and graduate students to enable them to find innovative solutions to formulation problems through research and implementation. Work will focus on understanding many of the long time problems associated with the compression of tablets, the development of formulations for new and existing molecules, and the measurements required to ensure proper delivery of formulations to a tablet press and the control of the press.
Together with Natoli Scientific, the Natoli Institute will provide resources to the tableting industry, including new product manufacturing studies, tablet tooling sticking and picking evaluations, and new formulation technologies. Not only does the facility provide an environment for students to learn industrial pharmacy unit operations for solid oral dosage forms, it also provides an opportunity for Natoli customers to have their tableting problems investigated, such as sticking, picking, tablet disintegration/dissolution, bioavailability, and formulation and feasibility experiments.
“We are committed to supporting the future of the industry, as well as providing additional resources to our customers to combat their tableting issues,” said Dale Natoli, company president.
Related News
-
News A Day in the Life of a Start-Up Founder and CEO
At CPHI we work to support Start-Up companies in the pharmaceutical industry and recognise the expertise and innovative angles they bring to the field. Through our Start-Up Programme we have gotten to know some of these leaders, and in this Day in the ... -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance